KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the...
Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (Provectus or the Company) (OTCQB: PVCT) today...
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (Provectus or the Company) (OTCQB:...
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (Provectus or the Company) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
Research on breast, colorectal, head and neck, and testicular cancersNovel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (Provectus or the...
PV-10 demonstrated significant anti-tumor activity in vivo in head and neck cancers KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (Provectus or the...
New Provectus Spinout Company Would Commercialize Combination Therapy of University's Light Source Medical Device and Provectus's Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March 27,...
Provectus Announces Award for U.S. Patents of Rose Bengal Sodium
Provectus Announces Acceptance of Cancer Immunotherapy PV-10 Abstract